Premium
Efficacy of sofosbuvir and ledipasvir in an HCV + gastro‐resected patient
Author(s) -
Taibi C.,
Tempestilli M.,
D'Avolio A.,
Garbuglia A. R.,
De Nicolò A.,
Montalbano M.,
D'Offizi G.
Publication year - 2017
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.12546
Subject(s) - ledipasvir , sofosbuvir , medicine , hepatitis c , chronic hepatitis , gastroenterology , surgery , virology , ribavirin , virus
Summary What is known and objective The second‐generation direct‐acting antivirals represented the first major turning point for the eradication of HCV infection in almost all settings of patients. However, no data were available on use in gastro‐resected patients. Case description We report on a gastrectomized patient with chronic hepatitis C infection. She was treated with sofosbuvir and ledipasvir ( SOF / LDV ) for 12 weeks, with measurement of blood levels of the drugs. She obtained sustained virological response at week 12 and 24 without dose adjustment. What is new and conclusion This case report can provide information useful for clinical practice in this set of patients and can open new perspectives in evaluating actual SOF / LDV bioavailability.